A new study in the journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are ...

The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.

Type I allergy, an IgE antibody triggered hypersensitivity disease, represents a common public health problem affecting about one third of the world´s population. Upon exposure to allergens, IgE ...

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s ...

A study has established the importance of immunoglobulin A, an antibody that is part of the immune system, in generating a response to pneumonia vaccines. Researchers have found that the absence of ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine-a bacterium that can cause various diseases, such as pneumonia.

To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the recombinant human monoclonal antibody Yervoy (ipilimumab) as a first-line ...

Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...